Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Agenus Inc. (AGEN : NSDQ)

• Company Description    Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts. Number of Employees: 81

• Price / Volume Information    Yesterday's Closing Price: $5.98 Daily Weekly Monthly 20 Day Moving Average: 10,743,602 shares Shares Outstanding: 44.75 (millions) Market Capitalization: $267.62 (millions) Beta: 1.55 52 Week High: $8.70 52 Week Low: $2.71 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 107.64% 106.11% 12 Week 52.94% 48.75% Year To Date 90.45% 82.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3 FORBES ROAD - LEXINGTON,MA 02421 USA ph: 781-674-4400 fax: 781-674-4200 investor@agenusbio.com http://www.agenusbio.com

• General Corporate Information    Officers Garo H. Armen - Chief Executive Officer and Chairman of the Board Austin Charette - Senior Director; Financial Reporting and Complianc Jennifer S. Buell - Director Brian Corvese - Director Tom Harrison - Director Peer Information Agenus Inc. (CORR.) Agenus Inc. (RSPI) Agenus Inc. (CGXP) Agenus Inc. (BGEN) Agenus Inc. (GTBP) Agenus Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00847G804 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 44.75 Most Recent Split Date: 4.00 (0.05:1) Beta: 1.55 Market Capitalization: $267.62 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.03 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.22 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 2.37 PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 2.16 EPS Growth vs. Year Ago Period: 199.03% vs. Previous Quarter: 82.14% Sales Growth vs. Year Ago Period: 40.18% vs. Previous Quarter: -1.37% ROE 06/30/26 - - 03/31/26 - -31.66 12/31/25 - -7.65 ROA 06/30/26 - - 03/31/26 - 42.71 12/31/25 - 11.01 Current Ratio 06/30/26 - - 03/31/26 - 0.38 12/31/25 - 0.41 Quick Ratio 06/30/26 - - 03/31/26 - 0.38 12/31/25 - 0.41 Operating Margin 06/30/26 - - 03/31/26 - 71.76 12/31/25 - 20.41 Net Margin 06/30/26 - - 03/31/26 - 50.49 12/31/25 - -2.67 Pre-Tax Margin 06/30/26 - - 03/31/26 - 50.46 12/31/25 - -2.70 Book Value 06/30/26 - - 03/31/26 - -5.94 12/31/25 - -8.17 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©